Portal de Periódicos da CAPES

Identification of distinct molecular subtypes of uterine carcinosarcoma

2017; Impact Journals LLC; Volume: 8; Issue: 9 Linguagem: Inglês

10.18632/oncotarget.15032

1949-2553

Yang An, Haojie Wang, Jingyao Jie, Yitai Tang, Weijuan Zhang, Shaoping Ji, Xiangqian Guo,

Ovarian cancer diagnosis and treatment

// Yang An 1, 2 , Haojie Wang 1, 2 , Jingyao Jie 1, 2 , Yitai Tang 3 , Weijuan Zhang 1, 2 , Shaoping Ji 1, 2, 4 , Xiangqian Guo 1, 2, 5, 6 1 Department of Biochemistry and Molecular Biology, Medical School, Henan University, Kaifeng 475004, China 2 Cell Signal Transduction Laboratory, Henan University, Kaifeng 475004, China 3 Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA 4 Department of Oncology, The First Affiliated Hospital of Henan University, Kaifeng, 475001, China 5 Department of Preventive Medicine, Medical School, Henan University, Kaifeng 475004, China 6 Department of Burn and Plastic Surgery, The Affiliated Nanshi Hospital of Henan University, Nanyang, 473003, China Correspondence to: Xiangqian Guo, email: xqguo@henu.edu.cn Shaoping Ji, email: shaopingji@163.com Keywords: uterine carcinosarcoma, molecular subtype, molecular signature, gene expression pattern, subtype-specific treatment Received: August 11, 2016 Accepted: January 06, 2017 Published: February 02, 2017 ABSTRACT Uterine carcinosarcoma (UCS) is a rare but lethal neoplasm with high metastasis and recurrence rate, and to date, no molecular classification of UCS has been defined to achieve targeted therapies. In this study, we identified two distinct molecular subtypes of UCS with distinct gene expression patterns and clinicopathologic characteristics. Subtype I UCS recapitulates low-grade UCS, in contrast subtype II UCS represents high-grade UCS with higher tumor invasion rate and tumor weight. Interestingly, subtype I UCS is characterized by cell adhesion and apoptosis pathways, whereas genes over-expressed in subtype II UCS are more involved in myogenesis/muscle development. We also proposed certain potential subtype specific therapeutic targets, such as SYK (spleen tyrosine kinase) for subtype I and cell-cycle proteins for subtype II. Our findings provide a better recognition of UCS molecular subtypes and subtype specific oncogenesis mechanisms, and can help develop more specific targeted treatment options for these tumors.